Option Care Health (OPCH) Earnings Date & Reports

Key Takeaways

• Option Care Health reported third quarter 2026 net revenue of $1.49 billion, up 4.1% year over year and modestly ahead of Wall Street consensus estimates.
• Adjusted diluted earnings per share (EPS) came in at $0.49, in line with analysts' expectations and up 8.9% from the prior-year quarter.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $124.6 million, a 4.3% year-over-year increase.
• GAAP (Generally Accepted Accounting Principles) diluted EPS rose 18.8% to $0.38, while GAAP net income grew 10.8% to $57.4 million.
• The company announced a definitive agreement to be acquired by Clayton, Dubilier & Rice and McKesson Corporation, and as a result withdrew its financial guidance and did not host an earnings call.
• For more context, explore the ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover actionable market ideas powered by AI by exploring Trending AI Robots.

Earnings Context and Why It Matters

Option Care Health is the nation's largest independent provider of home and alternate site infusion services, a category that continues to benefit as more complex therapies shift out of hospitals and into lower-cost community settings. Its quarterly results offer a read on payer reimbursement trends, chronic therapy volumes, and the economics of a national pharmacy and infusion-suite network. This particular report carries added weight because it arrives alongside a transformative corporate event: a pending acquisition by Clayton, Dubilier & Rice and McKesson Corporation. With guidance withdrawn and no earnings call held, investors are weighing the quality of the underlying operating results against a transaction that could meaningfully reshape the company's future trajectory.

Reported Results

For the third quarter ended September 30, 2026, Option Care Health reported net revenue of $1,493.5 million, an increase of 4.1% from $1,435.0 million in the prior-year period and slightly above consensus estimates near $1.48 billion. GAAP net income rose 10.8% to $57.4 million, translating to GAAP diluted EPS of $0.38, up 18.8% year over year.

On an adjusted basis, diluted EPS was $0.49, matching analysts' consensus expectations and improving 8.9% from $0.45 a year earlier. Adjusted EBITDA increased 4.3% to $124.6 million. Gross profit reached $285.0 million, up from $272.9 million in the same quarter last year, while cash provided by operating activities totaled $114.7 million.

Notably, the company disclosed a definitive merger agreement to be acquired by Clayton, Dubilier & Rice and McKesson Corporation. In connection with the transaction, management withdrew its previously issued financial guidance and suspended its customary earnings conference call, limiting forward-looking commentary in this report.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener supports the identification of trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. Whether you are monitoring names like OPCH or searching across entire industries, the AI Screener can help streamline your research workflow.

Market Reaction and Investor Sentiment

Shares of OPCH edged higher in the immediate aftermath of the release, with the stock reportedly rising roughly 1.9% as investors absorbed a revenue beat paired with an in-line adjusted EPS result. The narrow top-line outperformance and stable profitability provided a measure of reassurance, though the pending acquisition dominated the broader narrative. Because the company withdrew guidance and skipped its earnings call, traders had less qualitative detail to interpret, which can amplify uncertainty around the deal's timeline and closing conditions. Sentiment appears to reflect a balance between steady underlying operating performance and the structural questions raised by the change of control transaction.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most significant factor for OPCH shareholders is the progress and completion of the acquisition by Clayton, Dubilier & Rice and McKesson Corporation. Investors will be watching for regulatory approvals, the satisfaction of closing conditions, and any updates on transaction timing, since these elements are likely to outweigh near-term operating metrics in driving the stock.

Beyond the deal, several operating themes remain worth monitoring. Payer reimbursement rates and therapy mix across acute and chronic portfolios will continue to influence gross margin, which has shown modest year-over-year fluctuation. Volume trends in infusion therapies, along with the company's ability to manage selling, general, and administrative expenses, will shape profitability going forward.

Finally, with guidance withdrawn, market participants will need to rely more heavily on industry data and third-party estimates to gauge the company's trajectory. The combination of a solid quarter and a major corporate transaction makes OPCH a stock where both operational execution and merger milestones will command close attention in the months ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations